Nocturnal hypoglycemia: Answering the challenge with long-acting insulin analogs

MedGenMed Medscape General Medicine

Volumn 9, Issue 2, 2007, Pages

  Brunton, Stephen A ^a  

^a AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLUCAGON; GLUCOSE; GLUCOSE DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; DRUG DERIVATIVE;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; CLINICAL TRIAL; CONTINUOUS INFUSION; DIET RESTRICTION; DISEASE DURATION; DISEASE PREDISPOSITION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; NIGHT SLEEP; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PREVALENCE; REVIEW; RISK ASSESSMENT; SELF MONITORING; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; WEIGHT GAIN; COMORBIDITY; DIABETES MELLITUS; HYPOGLYCEMIA; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS; TREATMENT OUTCOME;

COMORBIDITY; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; INSULIN; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 34249339437     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S36.
2. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2002 update. Endocr Pract. 2002;8(suppl 1):40-82.
3. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
4. Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2005;18:83-91.
5. Matyka KA. Nocturnal hypoglycaemia in children: the effects on cognitive function. Diabetes Nutr Metab. 2002;15:390-394.
6. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9:530-543.
7. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs. 2003;63:1743-1778.
8. Home P, Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother. 2006;7:325-343.
9. Braunstein SN, White JR. Trends in the management of type 2 diabetes: an emerging role for insulin. J Managed Care Pharm. 2005;11:S2-S11.
10. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med. 2004;71:385-392, 394.
11. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
12. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
13. U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
14. Piche M-E, Arcand-Bosse J-F, Despres J-P, et al. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care. 2004;27:2470-2477.
15. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948-2961.
16. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20:S32-S42.
17. Matyka KA. Sweet dreams? - nocturnal hypoglycemia in children with type 1 diabetes. Pediatric Diabetes. 2002;3:74-81.
18. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med. 1991;90:450-459.
19. Yki-Jarvinen H. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue. Eur J Clin Invest. 2004;34:410-416.
20. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21:1477-1483.
21. Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62:187-195.
22. Devries JH, Wentholt IM, Masurel N, et al. Nocturnal hypoglycaemia in type 1 diabetes-consequences and assessment. Diabetes Metab Res Rev. 2004;20(suppl 2):S43-S46.
23. Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve Clin J Med. 2004;71:335-342.
24. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes. 2003;52:1195-1203.
25. Kaufman FR, Austin J, Neinstein A, et al. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr. 2002;141:625-630.
26. Gertzman J, White B, Streja D. Severity of hypoglycemia and hypoglycemia unawareness are associated with the extent of unsuspected nocturnal hypoglycemia. Diabetes. 2005;52(suppl 1):A146.
27. Bell SJ, Forse RA. Nutritional management of hypoglycemia. Diabetes Educ. 1999;25:41-47.
28. MacDonald MJ. Postexercise late-onset hypoglycemia in insulin-dependent diabetic patients. Diabetes Care. 1987;10:584-588.
29. Galassetti P, Mann S, Tate D, et al. Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab. 2001;280:E908-E917.
30. Kerr D, Macdonald IA, Heller SR, Tattersall RB. Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with type 1 (insulin-dependent) diabetes. Diabetologia. 1990;33:216-221.
31. Kolaczynski JW, Caro JF. Insulin resistance: site of the primary defect or how the current and the emerging therapies work. J Basic Clin Physiol Pharmacol. 1998;9:281-294.
32. Turner BC, Jenkins E, Kerr D, Sherwin RS, Cavan DA. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care. 2001;24:1888-1893.
33. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 1993;42:1233-1237.
34. Perros P, Deary IJ. Long-term effects of hypoglycaemia on cognitive function and the brain in diabetes. In: Frier BM, Fisher BM, eds. Hypoglycaemia in Clinical Diabetes. New York: John Wiley & Sons, Ltd: 1999:187-210.
35. Brands AMA, Biessels GJ, de Haan EHF, Kappelle LJ, Kessels RPC. Effects of type 1 diabetes on cognitive performance. Diabetes Care. 2005;28:726-735.
36. Matyka K, Ford-Adams M, Dunger DB. Hypoglycaemia and counterregulation during childhood. Horm Res. 2002;57(suppl 1):85-90.
37. Boland E, Monsod T, Delucia M, et al. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001;24:1858-1862.
38. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50.
39. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23:1-12.
40. Carroll MF, Burge MR, Schade DS. Severe hypoglycemia in adults. Rev Endocr Metab Disord. 2003;4:149-157.
41. Taira M, Takasu N, Komiya I, Taira T, Tanaka H. Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy. Metabolism. 2000;49:440-443.
42. Yale JF. Nocturnal hypoglycemia in patients with insulin-treated diabetes. Diabetes Res Clin Pract. 2004;65(suppl 1):S41-S46.
43. Bolli GB, Perriello G, Fanelli CG, De Feo P. Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care. 1993;16(suppl 3):71-89.
44. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4:673-682.
45. Lindstrom T, Olsson PO, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest. 2000;60:341-347.
46. Eli Lilly and Company. Re: Discontinuation of Humulin [R]U ULTRALENTE [R] (human insulin [rDNA origin] extended zinc suspension) and Humulin [R]L LENTE [R] (human insulin [rDNA origin] zinc suspension) [Dear Doctor Letter]. 2005. Available at: www.fda.gov/CDER/drug/shortages/ HumulinDr.pdf Accessed December 3, 2006.
47. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet. 1999;354:1604-1607.
48. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs. 2005;65:325-340.
49. Heinemann L, Sinha K, Weyer C, et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 1999;16:332-338.
50. Weinzimer SA, Doyle EA, Tamborlane WV. Disease management in the young diabetic patient: glucose monitoring, coping skills, and treatment strategies. Clin Pediatr. 2005;44:393-403.
51. Weinzimer SA, Doyle EA, Steffen AT, Sikes KA, Tamborlane WV. Rediscovery of insulin pump treatment of childhood type 1 diabetes. Minerva Med. 2004;95:85-92.
52. Doyle Boland EA, Steffen AT, Tamborlane WV. Case study: contrasting challenges of insulin pump therapy in a toddler and adolescent with type 1 diabetes. Diabetes Educ. 2005;31:584-590.
53. Goldman-Levine JD, Lee KW. Insulin detemir - a new basal insulin analog. Ann Pharmacother. 2005;39:502-507.
54. Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs. 2004;64:2577-2595.
55. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
56. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia. 2005;48:1988-1995.
57. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005;35:536-542.
58. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev. 2005;21:545-553.
59. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-1671.
60. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care. 2000;23:639-643.
61. Kudva YC, Basu A, Jenkins GD, et al. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care. 2005;28:10-14.
62. Ashwell S, Amiel S, Bilous R, et al. Improvement in HbA1c with insulin glargine + insulin lispro in comparison with NPH insulin+unmodified human insulin in people with type 1 diabetes. Diabetes. 2003;52(suppl 1):A442.
63. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004;21:1213-1220.
64. Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629.
65. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081-1087.
66. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther. 2004;26:724-736.
67. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med. 2005;22:850-857.
68. Kolendorf K, Ross GP, Pavlic-Renart I, et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabet Med. 2006;23:729-735.
69. Pieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med. 2007 Mar 22; [Epub ahead of print]
70. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care. 2003;26:799-804.
71. Robertson KJ, Schoenle E, Gucev Z, et al. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med. 2007;24:27-34.
72. Schober E, Schoenle E, Van DJ, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:369-376.
73. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
74. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138:952-959.
75. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189-196.
76. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
77. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451.
78. Rosenstock J, Schwartz SL, Clark CM, Jr., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
79. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [Correction appears in Raslova K, et al. Diabetes Res Clin Pract. 2006;72:112]. Diabetes Res Clin Pract. 2004;66:193-201.
80. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
81. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
82. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care. 2000;23:157-162.
83. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-1136.
84. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
85. Yki-Jarvinen H. The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: A meta-regression analysis in type 2 diabetes. Diabetes. 2003;52:A149-A150.